Loss of tumor suppressor gene function in human cancer: an overview

LH Wang, CF Wu, N Rajasekaran… - Cellular Physiology and …, 2019 - karger.com
Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two
types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. Extensive research …

Endometrial cancer

P Morice, A Leary, C Creutzberg, N Abu-Rustum… - The Lancet, 2016 - thelancet.com
Endometrial cancer is the most common gynaecological tumour in developed countries, and
its incidence is increasing. The most frequently occurring histological subtype is …

Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology

N Abu-Rustum, C Yashar, R Arend, E Barber… - Journal of the National …, 2023 - jnccn.org
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly
as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the …

Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology

WJ Koh, NR Abu-Rustum, S Bean, K Bradley… - Journal of the National …, 2018 - jnccn.org
Endometrial carcinoma is a malignant epithelial tumor that forms in the inner lining, or
endometrium, of the uterus. Endometrial carcinoma is the most common gynecologic …

Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and …

KJ Monahan, N Bradshaw, S Dolwani, B Desouza… - Gut, 2020 - gut.bmj.com
Heritable factors account for approximately 35% of colorectal cancer (CRC) risk, and almost
30% of the population in the UK have a family history of CRC. The quantification of an …

Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in collaboration with …

AN Bartley, AM Mills, E Konnick… - … of pathology & …, 2022 - meridian.allenpress.com
Context.—The US Food and Drug Administration (FDA) approved immune checkpoint
inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair …

[HTML][HTML] The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis

NAJ Ryan, MA Glaire, D Blake, M Cabrera-Dandy… - Genetics in …, 2019 - Elsevier
Purpose Endometrial cancer (EC) is often the sentinel cancer in women with Lynch
syndrome (LS). However, efforts to implement universal LS screening in EC patients have …

[HTML][HTML] Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 …

Y Antill, PS Kok, K Robledo, S Yip… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background In this study, we assessed the activity of durvalumab, an antibody to
programmed death ligand-1, in two cohorts of women with advanced endometrial cancers …

Endometrial cancer in Lynch syndrome

S Zhao, L Chen, Y Zang, W Liu, S Liu… - … Journal of Cancer, 2022 - Wiley Online Library
Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline
pathogenic variants (PVs) in mismatch repair (MMR) genes. LS‐associated endometrial …

Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer

AM Mills, S Liou, JM Ford, JS Berek… - The American journal …, 2014 - journals.lww.com
Lynch syndrome (LS) is an autosomal dominant inherited disorder caused by germline
mutations in DNA mismatch repair (MMR) genes. Mutation carriers are at substantially …